tiprankstipranks
Precigen Aligns Executive Incentives with FDA Approval Goals
Company Announcements

Precigen Aligns Executive Incentives with FDA Approval Goals

Pick the best stocks and maximize your portfolio:

An announcement from Precigen (PGEN) is now available.

Precigen, Inc. has incentivized its key employees, including top executives, with performance stock units (PSUs) which vest on reaching critical operational goals, aligning their interests with long-term shareholder value. These PSUs, part of the 2023 Omnibus Incentive Plan, will vest based on the submission and FDA approval of a Biologics License Application for a specific investigational product by the end of 2026. Vesting is contingent on continued employment and certain termination conditions, with provisions for accelerated vesting in the event of a change in control.

See more data about PGEN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPrecigen Reports Q3 2024 Financial Results
TheFlyPrecigen reports Q3 EPS (9c), consensus (8c)
Catie PowersPGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App